A single mutated enzyme, found in the cancer cells of some patients with acute myeloid leukemia or bile duct cancer, has become a precise target for a drug now in its fifth year of clinical use. Ivosidenib, sold as Tibsovo, works by jamming a specific biological switch. That switch, the IDH1 enzyme, when mutated, forces cells to churn out a compound called 2-hydroxyglutarate, or 2-HG. This compound is not a normal metabolic byproduct. It is an oncometabolite — a substance that actively drives cancer growth and blocks healthy cell maturation.
Ivosidenib stops that. By blocking the mutated IDH1, the drug cuts 2-HG levels. Cancer cells, no longer stuck in a proliferative state, begin to differentiate. They lose their malignant character and start behaving more like normal cells. The result is a reduction in the cancerous cell population and, for many patients, an easing of disease symptoms.
The drug first reached patients in July 2018. The U.S. Food and Drug Administration approved it then, designating it a first-in-class medication. That designation matters. It means ivosidenib was the first drug to work this way — a small molecule inhibitor aimed directly at a mutated IDH1 enzyme. Before that, doctors treating AML or cholangiocarcinoma had fewer options that targeted the specific genetic drivers of a patient’s cancer.
This is the logic of precision oncology. Instead of broad chemotherapy that hits all dividing cells, hard, the idea is to find the mutation that is pushing a particular cancer and block it. Ivosidenib fits that model. Its mechanism is narrow. It does not treat all AML or all cholangiocarcinoma. It treats only the subset of those cancers driven by an IDH1 mutation. That subset is not tiny, but it is specific. Testing for the mutation is required before a patient can receive the drug.
By May 2023, the drug had established itself as a standard option for these patients. The approval process itself was a sign of the shift in oncology. The FDA granted accelerated approval based on early trial data showing that ivosidenib could induce complete remissions in some relapsed or refractory AML patients. The logic was that a drug that so clearly hit a known target and produced such responses deserved early access. Later confirmatory trials backed that decision.
For cholangiocarcinoma, the bile duct cancer, the drug offered something similar. A subset of these patients carry the IDH1 mutation. Before ivosidenib, they had few effective treatments after standard chemotherapy failed. The drug gave them a targeted option where none existed.
The story of ivosidenib is not one of a cure. It is a story of a tool. A precise one. It does not work for everyone. It works for those whose cancer cells carry the right broken enzyme. For them, it can mean a reduction in tumor burden, a return to more normal blood cell counts, and time. Time that was not there before the drug existed.
That is the background against which this drug sits. Years of basic research into the metabolism of cancer cells, the identification of the IDH1 mutation in multiple tumor types, and the design of a molecule that could fit into the mutated enzyme and shut it down. The result is a treatment that does not just poison cells but redirects them. It is a different kind of attack on cancer, and as of July 2018, it became available to patients in the United States.
